JSC
AIMT

Jackson Square Capital’s Aimmune Therapeutics AIMT Stock Holding History

Jackson Square Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,394
Closed -$35K – 355
2020
Q1 		$35K Sell
2,394
-24,226
-91% -$619K 0.03% 138
2019
Q4 		$891K Buy
+26,620
New +$744K 0.51% 60

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Jackson Square Capital's AIMT Position: Q2 2020 in Review

Jackson Square Capital sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 2,394 shares — an estimated $35K sold.

Jackson Square Capital first reported a position in AIMT in Q4 2019 and held it in 2 quarters. The position peaked at $891K in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Jackson Square Capital reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Jackson Square Capital sold 2,394 Aimmune Therapeutics shares in Q2 2020, an estimated $35K.
  • Jackson Square Capital first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 2 quarters.
  • Jackson Square Capital's Aimmune Therapeutics position peaked at $891K in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Jackson Square Capital's 13F filing for Q2 2020, filed 18 Aug 2020.